Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Ibritumomab tiuxentan yttrium ttCD20.php on line 2
Ibritumomab tiuxentan yttrium ttCD20
LE WE PMID CA
Ibritumomab tiuxentan yttrium ttCD204141Ibritumomab Tiuxentan Yttrium ttCD20

81C6 ttTenascin

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (therapeutic use)

Atacicept ttBlys ttAPRIL

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Etanercept ttTNFalpha

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Figitumumab ttIGF1R

Galiximab ttCD80

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Ibritumomab tiuxentan yttrium ttCD20

Infliximab ttTNFalpha

Inotuzumab ozogamicin ttCD22

Ipilimumab ttCTLA4

Lymphoma (BASKET)

Lymphoma (Follicular)

Mepolizumab ttIL5

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ocrelizumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pertuzumab ttHER2

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

Solanezumab ttAmyloidBeta

T1H ttCD6

Tanezumab ttNGF

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2007  
1
Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
[19707332] Biologics 1(3): 215-27 (2007)
2009  
2
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.
[20616907] Onco Targets Ther 2(-): 199-208 (2009)
2010  
3
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
[20095035] Am J Hematol 85(2): 147-55 (2010)
2003  
4
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
[12777454] J Nucl Med Technol 31(2): 61-8; quiz 69-70 (2003)
2006  
5
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
[16826593] Cancer 107(4): 686-95 (2006)
2011  
6
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
7
Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Ibritumomab tiuxentan yttrium ttCD20.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Ibritumomab tiuxentan yttrium ttCD20.php on line 92